XOMA Royalty (NASDAQ:XOMA) Reaches New 1-Year High – Should You Buy?

XOMA Royalty Corporation (NASDAQ:XOMA) shares reached a new 52-week high during trading on Thursday . The company traded as high as $43.00 and last traded at $42.9850, with a volume of 71958 shares changing hands. The stock had previously closed at $42.62.

Analyst Upgrades and Downgrades

XOMA has been the topic of several recent analyst reports. Benchmark lowered shares of XOMA Royalty from a “buy” rating to a “hold” rating in a report on Friday, May 22nd. Lucid Cap Mkts downgraded XOMA Royalty from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. HC Wainwright lowered XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 target price on the stock. in a research note on Thursday, April 30th. Weiss Ratings raised XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 29th. Finally, Zacks Research upgraded shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 8th. One research analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, XOMA Royalty has a consensus rating of “Hold” and an average target price of $53.75.

XOMA Royalty Price Performance

The company has a market cap of $539.22 million, a price-to-earnings ratio of 27.39 and a beta of 0.86. The firm’s fifty day simple moving average is $41.69 and its 200 day simple moving average is $33.01. The company has a current ratio of 3.59, a quick ratio of 3.59 and a debt-to-equity ratio of 0.96.

XOMA Royalty (NASDAQ:XOMA) last posted its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). XOMA Royalty had a net margin of 53.46% and a return on equity of 12.56%. The business had revenue of $12.32 million during the quarter, compared to analyst estimates of $13.91 million. Sell-side analysts predict that XOMA Royalty Corporation will post 0.9 earnings per share for the current year.

Hedge Funds Weigh In On XOMA Royalty

Hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its stake in XOMA Royalty by 207.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 133,360 shares of the biotechnology company’s stock worth $4,182,000 after acquiring an additional 90,025 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of XOMA Royalty by 9.7% in the first quarter. Bank of New York Mellon Corp now owns 74,984 shares of the biotechnology company’s stock valued at $2,352,000 after acquiring an additional 6,600 shares during the period. Opaleye Management Inc. grew its position in shares of XOMA Royalty by 14.7% during the fourth quarter. Opaleye Management Inc. now owns 292,590 shares of the biotechnology company’s stock worth $7,780,000 after acquiring an additional 37,503 shares during the last quarter. Squarepoint Ops LLC acquired a new position in shares of XOMA Royalty in the 4th quarter valued at $237,000. Finally, Panagora Asset Management Inc. increased its holdings in shares of XOMA Royalty by 24.2% in the 4th quarter. Panagora Asset Management Inc. now owns 21,229 shares of the biotechnology company’s stock valued at $564,000 after acquiring an additional 4,135 shares during the period. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.